Rebound congestion Rebound congestion, or rhinitis medicamentosa, may occur. A 2006 review of the pathology of rhinitis medicamentosa concluded that use of<unk>  for more than three days may result in rhinitis medicamentosa and recommended limiting use to three days. In a submission to the Therapeutic Goods Administration, a Novartis representative concluded, "The justification was not based on evidence." Citing an existing extensive body of evidence and noting a range of recommended periods from five to ten days, Novartis recommended the established five day period for its use for self-medication without medical consultation as it coincides with the typical duration of the common cold. Use in pregnancy The Food and Drug Administration places<unk>  in category C, indicating risk to the fetus cannot be ruled out. While it has been shown that a single dose does not significantly alter either maternal or fetal circulation, this subject has not been studied extensively enough to draw reliable conclusions.
Oxymetazoline
Xylometazoline
Methylergometrine
Erythrocrine
Terbutaline
Terazosin
Papaverine
Dihydroergotamine